These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Arrestin-3 Agonism at Dopamine D Schamiloglu S; Lewis E; Keeshen CM; Hergarden AC; Bender KJ; Whistler JL Biol Psychiatry; 2023 Oct; 94(7):531-542. PubMed ID: 36931452 [TBL] [Abstract][Full Text] [Related]
3. Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D Kiss B; Krámos B; Laszlovszky I Front Psychiatry; 2022; 13():785592. PubMed ID: 35401257 [TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Nakamura T; Kubota T; Iwakaji A; Imada M; Kapás M; Morio Y Drug Des Devel Ther; 2016; 10():327-38. PubMed ID: 26834462 [TBL] [Abstract][Full Text] [Related]
5. Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia. Sun X; Gou HY; Li F; Lu GY; Song R; Yang RF; Wu N; Su RB; Cong B; Li J Acta Pharmacol Sin; 2016 Mar; 37(3):322-33. PubMed ID: 26775662 [TBL] [Abstract][Full Text] [Related]
7. Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC. Hida H; Mouri A; Mori K; Matsumoto Y; Seki T; Taniguchi M; Yamada K; Iwamoto K; Ozaki N; Nabeshima T; Noda Y Neuropsychopharmacology; 2015 Feb; 40(3):601-13. PubMed ID: 25120077 [TBL] [Abstract][Full Text] [Related]
8. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia. Gross G; Wicke K; Drescher KU Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852 [TBL] [Abstract][Full Text] [Related]
9. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Kiss B; Laszlovszky I; Horváth A; Némethy Z; Schmidt E; Bugovics G; Fazekas K; Gyertyán I; Agai-Csongor E; Domány G; Szombathelyi Z Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280 [TBL] [Abstract][Full Text] [Related]
10. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Gyertyán I; Sághy K; Laszy J; Elekes O; Kedves R; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Agai Csongor E; Domány G; Kiss B; Szombathelyi Z Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):529-39. PubMed ID: 18548231 [TBL] [Abstract][Full Text] [Related]
11. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Heidbreder CA; Gardner EL; Xi ZX; Thanos PK; Mugnaini M; Hagan JJ; Ashby CR Brain Res Brain Res Rev; 2005 Jul; 49(1):77-105. PubMed ID: 15960988 [TBL] [Abstract][Full Text] [Related]
12. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Millan MJ; Seguin L; Gobert A; Cussac D; Brocco M Psychopharmacology (Berl); 2004 Jul; 174(3):341-57. PubMed ID: 14985929 [TBL] [Abstract][Full Text] [Related]
13. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. Millan MJ; Peglion JL; Vian J; Rivet JM; Brocco M; Gobert A; Newman-Tancredi A; Dacquet C; Bervoets K; Girardon S J Pharmacol Exp Ther; 1995 Nov; 275(2):885-98. PubMed ID: 7473180 [TBL] [Abstract][Full Text] [Related]
15. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181 [TBL] [Abstract][Full Text] [Related]
16. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Wadenberg ML Neurosci Biobehav Rev; 1996; 20(2):325-39. PubMed ID: 8811720 [TBL] [Abstract][Full Text] [Related]
17. Agents acting on central dopamine receptors. Kumar N; Jain PC Prog Drug Res; 1977; 21():409-65. PubMed ID: 22892 [No Abstract] [Full Text] [Related]
18. The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Millan MJ; Gressier H; Brocco M Eur J Pharmacol; 1997 Mar; 321(3):R7-9. PubMed ID: 9085054 [TBL] [Abstract][Full Text] [Related]